Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Innovent Biologics Inc / Equity Capital Markets

<p>Innovent Biologics is raising up to USD 500 million via a listing on the Hong Kong Stock Exchange. In this insight, we will discuss the following topics:</p>
<ul>
<li>The company's background</li>
<li>Details and competitors of its one novel and three biosimilar drug candidates</li>
<li>Potential market size for the key products</li>
<li>Shareholders and investors</li>
<li>Summary of our likes and concerns</li>
<li>Questions for management meetings</li>
</ul>
<p>We will leave the discussion of valuation for our next insight.</p>

Innovent Biologics is raising up to USD 500 million via a listing on the Hong Kong Stock Exchange. In this insight, we will discuss the following topics:

The company's background
Details and competitors of its one novel and three biosimilar drug candidates
Potential market size for the key products
Shareholders and investors
Summary of our likes and concerns
Questions for management meetings

We will leave the discussion of valuation for our next insight.

Innovent Biologics (信达生物) IPO: A Major PD-1 MAb Competitor Might Have Just Emerged (Part 1)

China

Innovent Biologics, Inc. operates as a biopharmaceutical company. The Company develops, manufactures, and distributes monoclonal antibody drug candidates for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and other diseases. Innovent Biologics serves customers in China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Innovent Biologics Inc (1801 HK)

Innovent Biologics (信达生物) IPO: A Major PD-1 MAb Competitor Might Have Just Emerged (Part 1)

Innovent Biologics is raising up to USD 500 million via a listing on the Hong Kong Stock Exchange. In this insight, we will discuss the following...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)